Zai Lab (ZLAB) said Thursday that results from the ongoing phase 1a/1b trial of ZL-1310 in people with extensive-stage small cell lung cancer following at least one previous platinum-based chemotherapy treatment showed "promising" objective response rates and safety profile.
The objective response rate was 74% in all tested dose levels of ZL-1310 in people with the disease, the company said.
The firm showcased the data at the conference in Barcelona regarding the current phase 1a part of the research, which involves increasing the dosage of the drug in four different groups, including outcomes from a total of 25 participants.
"ZL-1310 anti-tumor activity was demonstrated across all dose levels," Zai Lab said.
Also, ZL-1310 was "well tolerated across all dose levels with the majority of treatment-emergent adverse events (TEAE) being Grade 1 or 2," the company said.
The shares of Zai Lab were rising past 15% in recent trading.
Price: 33.41, Change: +4.47, Percent Change: +15.45
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。